Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Arius Research has said that in preclinical studies the company's anti-CD9 cancer stem cell antibody not only targeted leukemia cancer stem cells, but also led to a dramatic reduction in their capacity to self-renew or give rise to further leukemia.
Subscribe to our email newsletter
The company has disclosed the activity of Arius’s anti-CD9 antibody, AR40A746.2.3, against acute myeloid leukemia (AML). CD9 appears to be an important driver for leukemia and potentially other cancer stem cells, which often survive treatment, continue to multiply and go on to seed new tumors.
Daniel Pereira, vice president of research at Arius, said: “Our antibody also appears to be a specific cancer stem cell inhibitor, suggesting that it may become an important drug and forge new paths for the treatment of cancer.”